| 产品名称 | SU 6668 - TSU 68 | Orantinib |
| 产品货号 | Axon 1891 CAS [252916-29-3] MF C18H18N2O3MW 310.35 Purity: 98% Soluble in 0.1N NaOH(aq) and DMSO Description An ATP-competitive, orally bioavailable receptor tyrosine kinase (RTK) inhibitor targeting PDGFR, VEGF and FGFR (IC50 values are 0.06, 2.43, 3.04 and >100 μM at PDGFRβ, VEGFR2, FGFR1 and EGFR respectively) References Certificates Categories Extra info L Sun et al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem. 1999, 42(25), 5120-5130. AD Laird et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60(15), 4152-4160. M Toi et al. A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Breast Cancer. 2014, 21(1), 20-27. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology VEGFR PDGFR RTK class III, IV and V; EC 2.7.10.1 FGFR Inhibitor of RTK targeting PDGFR, VEGF and FGFR Chemical name 3-(2,4-dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid Parent CAS No. [252916-29-3] Order Size Unit Price Stock 10 mg €105.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
SU 6668 - TSU 68 | OrantinibAxon 1891 CAS [252916-29-3] MF C18H18N2O3
Description
An ATP-competitive, orally bioavailable receptor tyrosine kinase (RTK) inhibitor targeting PDGFR, VEGF and FGFR (IC50 values are 0.06, 2.43, 3.04 and >100 μM at PDGFRβ, VEGFR2, FGFR1 and EGFR respectively)
Inhibitor of RTK targeting PDGFR, VEGF and FGFR
Chemical name3-(2,4-dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid Parent CAS No.[252916-29-3] |
| 产品资料 |
